European Patent Office to Grant Biomoda Patent
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application related to a method of using Biomoda’s proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples.